Figure 7.

Effects of targeting GSK-3 in leukemia. Targeting of GSK-3 can interrupt important points in leukemogenesis. (a) Targeting GSK-3 may inhibit the activity of critical transcription factors such as CREB that are important in LICs. (b) Targeting GSK-3 may inhibit suppression of p27^Kip-1, and thus cell cycle arrest will occur. Open p27^Kip-1 means degraded protein. (c) It may also be important in certain instances to target β-catenin with drugs such as indomethacin as β-catenin levels will increase when GSK-3 is inhibited. (d) Inhibiting GSK-3 prevents the phosphorylation of LRP5/6 that prevents β-catenin stabilization. This figure is provided to elicit the possibility of targeting GSK-3 in leukemia.